<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849860</url>
  </required_header>
  <id_info>
    <org_study_id>V01-121A-501</org_study_id>
    <nct_id>NCT02849860</nct_id>
  </id_info>
  <brief_title>Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris</brief_title>
  <official_title>A Phase 1b Open-Label Study Evaluating the Absorption and Systematic Pharmacokinetics of Topically Applied IDP-121 Lotion in Subjects With Acne Vulgaris Under Maximal Use Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-Label study designed to assess the safety and plasma PK of tretinoin and relevant
      metabolites after topical dermal application of IDP-121 lotion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-Label study designed to assess the safety and plasma PK of tretinoin and relevant
      metabolites after topical dermal application of IDP-121 lotion in subjects with moderate to
      severe acne vulgaris under maximal use conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluators Global Severity Score at Day 15</measure>
    <time_frame>15 Days</time_frame>
    <description>Acne severity will be determined by the investigator/evaluator based on a global assessment of the inflammatory and non-inflammatory lesions of facial acne. Evaluations will be graded on a static scale ranging from 0 (clear) to 4 (severe).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>IDP-121 Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lotion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-121 Lotion</intervention_name>
    <description>Lotion</description>
    <arm_group_label>IDP-121 Lotion</arm_group_label>
    <other_name>Lotion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female, between the ages of 9 and &lt;17 years (16 years 11 months inclusive).

          -  Written and oral informed consent must be obtained. Subjects less than age of consent
             must sign an assent for the study and a parent or legal guardian must sign the
             informed consent.

          -  Subject must have a score of 3 (moderate) to 4 (severe) on the Evaluator's Global
             Severity Assessment at the screening and baseline visit in the facial area.

          -  Subjects with facial acne inflammatory lesions count no less than 20 but no more than
             40.

          -  Subjects with facial acne non-inflammatory lesions count no less than 20 but no more
             than 100.

        Key Exclusion Criteria:

          -  Use of investigational drug or device within 30 days of enrollment or participation in
             research study or concurrent study with this study.

          -  Any dermatological conditions on the face that could interfere with clinical
             evaluations acne conglobate, acne fulminans, secondary acne, perioral dermatitis,
             clinical significant rosacea, gram negative folliculitis.

          -  Any underlying disease(s) or some other dermatological condition of the face that
             requires the use of interfering topical or systemic therapy or makes evaluations and
             lesion count inconclusive.

          -  Subjects with facial beard or mustache that could interfere with any study
             assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anya Loncaric</last_name>
    <role>Study Director</role>
    <affiliation>Valeant Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valeant Site 02</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeant Site 01</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

